patent.fyi
Applications  /  US 2026/0355169
United States Patent Application Publication

US 2026/0355169 A1

Published
Nov 12, 2026
Filed
Oct 13, 2023
Earliest date on the face
Oct 14, 2022
Classification
A61K 31/444
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Antibody delivery of a cytotoxin

What ifWhat if treatment uses an antibody linked to a microtubule inhibitor and directed at a tumor cell surface receptor?
Claim language“a compound of Formula (0)”

The antibody binds an extracellular receptor on the tumor cell, and the cell internalizes the complex. Lysosomal proteases cleave the linker and release the inhibitor, which disrupts microtubule assembly.

1.2Oxygen in a contracted ring

What ifWhat if a five-membered furan ring replaces the ring containing X and places oxygen at the corresponding edge of the fused core?
Claim language“X is CRX or N”

The furan shares two adjacent carbon atoms with a benzene ring to form a planar benzofuran core. Substituents on the fused system project from its perimeter, and the furan oxygen supplies a hydrogen-bond acceptor.

1.4Terminal amine on the side chain

What ifWhat if a terminal dimethylamino group replaces the listed substituents on the alkyl side chain at X?
Claim language“one or more halogen, cyano, oxo, or OH”

A two-carbon chain joins the core carbon at X to a terminal dimethylamino group. Protonation at the tertiary amine creates a water-soluble salt form for aqueous formulation.

1.6Nitrile at the W1 carbon

What ifWhat if the W1 carbon carries a nitrile group?
Claim language“RW1 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl”

The nitrile carbon bonds directly to the W1 ring carbon through a single bond. The carbon–nitrogen triple bond gives the substituent a linear shape and places a hydrogen-bond acceptor at its tip.

1.9Hydroxyl on the alkyl substituent

What ifWhat if the alkyl substituent at W2 carries a terminal hydroxyl group in place of the halogen substitution?
Claim language“optionally substituted with one or more halogen”

A two-carbon chain attaches to the W2 ring carbon and terminates in a primary alcohol. The terminal hydroxyl donates and accepts hydrogen bonds and increases hydration at the end of the chain.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Specific version of a part

Pyridine nitrogen at W1

W1 is a pyridine-type nitrogen bonded to the two adjacent atoms of the aromatic ring. Its lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.

Hydrogen-bearing carbon at W2

W2 is an aromatic carbon bonded to one hydrogen and to its two ring neighbors. Its perpendicular p orbital participates in the conjugated ring system.

Fluorine at the W2 carbon

RW2 is a fluorine atom bonded directly to the aromatic carbon at W2. The polarized carbon–fluorine bond changes the local electron distribution at that position.

Terminal ethynyl group at W3

RW3 is a two-carbon ethynyl group attached through one of its triple-bonded carbons to the W3 ring carbon. The distal carbon bears a hydrogen, and the triple bond holds the substituent along a linear axis.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2006/0293328 A1
Published
Dec 28, 2006
Filed
May 17, 2006
Class
A61K 31/505
Document BUS 10,080,739 B2
Published
Sep 25, 2018
Filed
Jan 22, 2015
Class
A61K 31/4184
Claim 1
Document A
Document B
1.1administering to the subject a compound of Formula (0): an isomer thereof, or a pharmaceutically acceptable salt thereof
The methods for treating microbial infections comprise administering to a subject in need thereof an active compound as described herein. These active compounds, as set forth above, include compounds of Formula (I-V), their corresponding prodrugs, and pharmaceutically acceptable salts of the compounds and prodrugs.
A · US 2006/0293328 A1 · ¶ 266
A method of treating cancer in a mammal, comprising administering to said mammal an effective amount of a compound of formula (VI): or a pharmacologically acceptable salt thereof, wherein: R4, R5, R7 and R8 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, subst
B · US 10,080,739 B2 · claim 1
1.2wherein: X is CRX or N
1.3RX is H, halogen, cyano, oxo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy
Ar1 and Ar3 are independently selected from the group consisting of: wherein: A, Y, and Z are independently selected from the group consisting of N and CR4, and wherein R4 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl;
A · US 2006/0293328 A1 · claim 37
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl
B · US 10,080,739 B2 · claim 1
1.4wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy is optionally substituted with one or more halogen, cyano, oxo, or OH
Alkyl groups can optionally be substituted (a “substituted alkyl”) with one or more alkyl group substituents, which can be the same or different. The term “alkyl group substituent” includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.
A · US 2006/0293328 A1 · ¶ 91
1.5W1 is N or CRW1
1.6RW1 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl
B · US 10,080,739 B2 · claim 1
1.7W2 is N or CRW2
1.8RW2 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl
B · US 10,080,739 B2 · claim 1
1.9wherein the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally substituted with one or more halogen
Alkyl groups can optionally be substituted (a “substituted alkyl”) with one or more alkyl group substituents, which can be the same or different. The term “alkyl group substituent” includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.
A · US 2006/0293328 A1 · ¶ 91
1.10W3 is N or CRW3
1.11RW3 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl
B · US 10,080,739 B2 · claim 1
1.12W4 is N or CRW4 RW4 is H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or S(C1-C6 alkyl) R1 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1a each R1a independently is halogen, cyano, oxo, OH, NH2, NHC(═O)O(C1-C6 alkyl), N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl R2 is H, halogen, cyano, oxo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy R3 is H, halogen, cyano, oxo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy or R1 and R3, together with the intervening atoms, form a 4- to 12-membered heterocycloalkyl optionally substituted with one or more oxo X1 is —NRX1—*, —C(═O)NRX1—*, —NRX1C(═O)—*, —NRX1C(═O)O—*, —NRX1N═C—*, —NRX1C(═NRX1)—*, —N C(═NH)NRX1—*, —NRX1C(═O)NRX1—*, —S(═O)2NRX1—*, or —NRX1S(═O)2—* wherein * denotes attachment to A RX1 independently is H, S(═O)2RX1a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more RX1a each RX1a independently is halogen, C1-C6 alkyl, or 3- to 12-membered heterocycloalkyl wherein the C1-C6 alkyl, or 3- to 12-membered heterocycloalkyl is optionally substituted with one or more halogen A is C1-C6 alkyl, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl) wherein the C1-C6 alkyl, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl) is optionally substituted with one or more RA each RA independently is halogen, cyano, oxo, OH, ORA1, NH2, NHRA1, N(RA1)2, (═N)RA1, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more RA1 each RA1 independently is halogen, cyano, oxo, OH, ORA2, NH2, NHRA2, N(RA2)2, C(═O)RA2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more RA2 each RA2 independently is halogen, cyano, OH, NH2, N(RA3)2, C(═O)RA3, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl wherein RA3 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.
Ar2 is selected from the group consisting of: wherein: A1, A2, A3, Y1, Y2, Y3, Z1, Z2, and Z3 are independently selected from the group consisting of N and CR7, and wherein R7 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl; each m is independently an integer from 0 to 4; each t is independently an integer from 0 to 6; each R5, R6, R8, R9 and R10 is independently selected from the group
A · US 2006/0293328 A1 · claim 37

An empty cell means only that no passage was reproduced there.

Statements in these documents
The presently disclosed subject matter relates to methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues, processes for synthesizing novel dicationic terphenyl compounds and their aza analogues, and the novel dicationic terphenyl compounds and their aza analogues themselves.
A · US 2006/0293328 A1 · ¶ 2
Thus, there continues to be a need for improvement in the art for additional compounds having desirable antimicrobial activity, whether against the representative pathogens referenced above or against other pathogens.
A · US 2006/0293328 A1 · ¶ 60
This invention pertains to the field of anti-cancer compounds and, in particular, to the use of therapeutically active 2,4,5-trisubstituted imidazole compounds in the treatment of cancer.
B · US 10,080,739 B2 · ¶ 2
The research in this field is therefore mainly directed to the synthesis of anticancer agents which would possess high antineoplastic activity, low systemic toxicity and low mutagenicity on normal cells.
B · US 10,080,739 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355169 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355169/, SHA-256 a878ddb46828e9c0540f2ec26ac6130577f8a897124d45c33638bb27763d0b74
First published
Permanent addresshttps://patent.fyi/US20260355169/
Content fingerprint (SHA-256)a878ddb46828e9c0540f2ec26ac6130577f8a897124d45c33638bb27763d0b74
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi